

Clinical trial readiness study of distal myopathy and dysphagia in nephropathic cystinosis

Reza Sadjadi MD¹  | Stacey Sullivan MS, CCC-SLP² | Natalie Grant BA³ | Susan E. Thomas MD⁴ | Maya Doyle MSW, PhD, LCSW⁵ | Colleen Hammond RN⁶ | Camille Corre BS/BA⁷ | Nicholas Mello BS⁷ | William S. David MD, PhD¹ | Florian Eichler MD⁷

¹Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts

²Department of Speech, Language and Swallowing Disorders, Massachusetts General Hospital, Boston, Massachusetts

³Center for Rare Neurological Diseases, Massachusetts General Hospital, Boston, Massachusetts

⁴Division of Pediatric Nephrology, Department of Pediatrics and Communicable Diseases, University of Michigan School of Medicine, Ann Arbor, Michigan

⁵Department of Social Work, School of Health Sciences, Quinnipiac University, Hamden, Connecticut

⁶Cystinosis Adult Care Excellence Initiative, Reading, Massachusetts

⁷Center for Rare Neurological Diseases, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts

Correspondence

Reza Sadjadi, Department of Neurology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114.
Email: rseyedsadjadi@mgh.harvard.edu

Funding information

Cystinosis Research Foundation

Abstract

Background: Nephropathic cystinosis is a lysosomal storage disorder with late-onset systemic complications, such as myopathy and dysphagia. Currently employed outcome measures lack sensitivity and responsiveness for dysphagia and myopathy, a limitation to clinical trial readiness.

Methods: We evaluated 20 patients with nephropathic cystinosis in two visits over the course of a year to identify outcomes sensitive to detect changes over time. Patients also underwent an expiratory muscle strength training program to assess any effects on aspiration and dysphagia.

Results: There were significant differences in the Timed Up and Go Test (TUG) and Timed 25-Foot Walk (25-FW) between baseline and 1-y follow-up ($P < .05$). Maximum expiratory pressure (MEP) and peak cough flow (PCF) significantly improved following respiratory training ($P < .05$).

Conclusions: Improved respiratory outcomes may enhance patients ability to expel aspirated material from the airway, stave off pulmonary sequelae associated with chronic aspiration, and yield an overall improvement in physical health and well-being.

KEYWORDS

distal myopathy, dysphagia, EMST150, nephropathic Cystinosis, respiratory therapy, video fluoroscopy

1 | INTRODUCTION

Nephropathic cystinosis is a rare autosomal recessive lysosomal storage disorder caused by mutations in the cystinosis gene (*CTNS*),

leading to impairment in the lysosomal membrane transport complex.¹⁻⁵ Patients often present with early failure to thrive and Fanconi syndrome.^{6,7} The free cystine crystal deposition in different tissues including muscle leads to clinical myopathy characterized pathologically by the presence of autophagic, acid phosphatase positive vacuoles in muscle tissues^{8,9} and cystine crystals within perimysial collagen fibrils.⁵ Oral beta-mercaptoethylamine (cysteamine) facilitates cystine transportation from the lysosome through an alternative lysine transporter¹⁰⁻¹² and lowers cystine levels in the muscle tissue.¹³⁻¹⁸ Nevertheless, patients continue to have significant non-renal

Abbreviations: 25-FW, Timed 25-Foot Walk; 9-HPT, 9-Hole Peg Test; ACE, Adult Care Excellence Initiative; ALS, amyotrophic lateral sclerosis; ASHA, American Speech and Hearing Association; DMFS, Distal Myopathy Function Scale; EAT-10, The 10-item Eating Assessment Tool; EMST, Expiratory Muscle Strength Trainer; IQR, interquartile range; MDADI, M. D. Anderson Dysphagia Inventory; MEP, maximum expiratory pressure; PAS, Penetration-Aspiration Scale; PCF, peak cough flow; QOL, quality of life; SLP, speech language pathologist; TUG, Timed Up and Go test; VFSS, video fluoroscopy swallow study.

morbidity and mortality primarily due to muscle weakness,¹⁹⁻²¹ swallowing difficulties²² and aspiration.²³

There is an increasing awareness that clinical myopathy and dysphagia are common, even in the absence of clinically overt muscle weakness.^{16,18,20-22,24-26} Respiratory muscle weakness can be life threatening.²⁷ In addition, oropharyngeal dysphagia may give rise to aspiration pneumonia and other respiratory complications.²⁸ It is imperative to develop clinical trial readiness studies to better understand the natural history of the disease, changes in clinically relevant outcome measures, guidance on care standards, and biomarkers that ascertain disease severity or drug response.

Improved swallowing efficiency and elevated tolerance of aspiration can allow a patient to liberalize diet and improve overall quality of life.²⁹ Expiratory Muscle Strength Trainer (EMST) is an intervention applied in healthy individuals and in patients with the goals of increasing the force-generating capacity of the expiratory muscles and improving pulmonary function.³⁰ EMST is feasible and well tolerated in neurological conditions with prominent dysphagia, improving expiratory force-generating pressures and swallowing kinematics.³¹⁻³³ The activation of expiratory musculature is implicated in the force generation of cough.³⁴ Individuals with chronic dysphagia and associated aspiration, such as in the cystinosis population, benefit from a holistic approach to swallowing management, which includes exercise aimed at improving oral, pharyngeal, and laryngeal physiological function in concert with interventions aimed to protect and clear the airway. Interventions targeted to improve cough, such as expiratory muscle strength training, are an essential component of whole patient focused dysphagia management.

Through collaboration with the members of the Adult Care Excellence (ACE) Initiative³⁵ and access to the results of qualitative surveys³⁶⁻³⁸ from adults patients with nephropathic cystinosis, we determined that swallowing difficulties and muscle weakness were the most pressing concerns affecting quality of life and function. In the first phase of this study, we characterized clinical myopathy, muscle weakness and dysphagia in patients with nephropathic cystinosis and proposed a new disease-specific functional clinical outcome measure to better quantify disease progression in this patient population.²⁵ In this longitudinal follow-up study, we sought to: (1) further characterize the evolution of the myopathy and dysphagia; (2) evaluate the sensitivity and responsiveness of currently used strength, swallowing, and respiratory outcomes; and (3) evaluate the feasibility of EMST and its impact on swallowing and respiratory outcome measures.

2 | METHODS

The study was approved by the research ethics committee, Partners Institutional Review Board at Massachusetts General Hospital. Informed consent was obtained in accordance with Institutional Review Board procedures.

Patients with confirmed nephropathic cystinosis, based on elevated leukocyte cystine levels, the presence of crystals in the cornea, or genetic mutation testing, had two visits (visit 1 and 2) 1 y apart. Following the second visit, patients underwent a 5-wk exercise

regimen using an EMST150 expiratory muscle strength training program. At the completion of the training regimen, patients had an additional visit (visit 3) to identify any effect on aspiration and dysphagia and breathing outcomes.

2.1 | Clinical study

Patients had a neuromuscular examination, including manual muscle testing of proximal and distal upper and lower extremities, video fluoroscopic swallowing evaluation, and pulmonary function testing at each visit. Patients completed patient-reported measures (The M. D. Anderson Dysphagia Inventory³² [MDADI] and The 10-item Eating Assessment Tool³³ [EAT-10]), and clinical outcome measures (9-Hole Peg Test [9-HPT], Timed 25-Foot Walk [25-FW], Timed Up and Go Test [TUG], and grip myometry).

2.2 | EMST training

EMST150 (Aspire Products; Gainesville, FL, USA) is a handheld device that houses a calibrated spring loaded valve designed to improve activation of the expiratory and submental muscles through resistance training.³⁹ A 5-wk exercise protocol using this trainer commenced immediately following visit 2. EMST150 was used with the trainer set at 50% of a patient's individual maximum expiratory pressure (MEP), representing a moderate load on the expiratory muscles. A flanged rubber mouthpiece was attached to the opening of the trainer to help create a tight lip seal. For those that did not meet the threshold requirements (MEP > 60 cm H₂O), we did not calibrate the device and left it at 30 cm H₂O, the lowest resistance pressure. There was one patient who could not achieve a lip seal around the flanged rubber mouthpiece due to lip and facial weakness. She used a mask that created a seal around the entire mouth and nose and expelled air through the device in this manner. To measure adherence to the treatment protocol, each day of training, patients submitted a video clip of themselves using the EMST150 device along with verbal confirmation of the level they were using.

2.3 | Patient-reported outcomes

The MDADI is a self-administered 20-item questionnaire designed to evaluate the impact of dysphagia on the quality of life (QOL) of patients with head and neck cancer, which we adopted for this study of patients with nephropathic cystinosis. MDADI scores range between 20 and 100, with a higher score representing better function and QOL. The EAT-10 is a self-administered, symptom-specific outcome instrument for dysphagia used in various conditions including neurodegenerative diseases. The EAT-10 scores range between 0 and 40, with higher scores representing more severe dysphagia. Normative data suggest that an EAT-10 score of 3 or higher is considered abnormal.

TABLE 1 Clinical and patient-reported outcome measures for visits 1, 2, and 3 and between visit comparisons

Units	Visit 1		Visit 2		Visit 3		Visits 1-2 P-value	Visits 2-3 P-value
	Mean (95%CI)	Median (IQR)	Mean (95%CI)	Median (IQR)	Mean (95%CI)	Median (IQR)		
MEP	64.2 (45.9;82.5)	64.4 (29.0;91.5)	63.4 (45.4;81.4)	69.5 (30.3;86.7)	80.9 (60.4;101.5)	94.0 (43.3;106.7)	.781	<.001*
PCF	249.0 (193.3;304.7)	269.3 (97.3;345.0)	233.2 (184.9;281.5)	253.3 (123.3;293.3)	259.0 (207.5;310.5)	293.4 (146.7;346.7)	.324	.022*
Grip	23.2 (16.5;29.8)	21.0 (17.2;26.3)	22.2 (17.6;26.7)	21.2 (16.7;27.4)	19.7 (15.4;24.0)	20.9 (17.5;24.8)	.546	.131
9-HPT	23.3 (20.5;26.2)	21.7 (20.3;25.2)	22.7 (19.7;25.8)	21.0 (18.6;25.5)	22.4 (19.2;25.7)	21.5 (18.1;23.9)	.413	.726
TUG	7.0 (6.3;7.8)	7.3 (5.8;8.2)	7.9 (7.0;8.8)	7.7 (6.4;8.6)	8.1 (6.9;9.3)	7.6 (6.3;9.2)	.002*	.870
25-FW	4.9 (4.5;5.4)	5.1 (3.9;5.6)	5.7 (5.2;6.3)	5.3 (4.9;6.4)	5.7 (5.2;6.3)	5.5 (4.8;6.4)	<.001*	.288
MDADI-E	24.5 (22.8;26.1)	25.0 (22.5;26.0)	23.3 (20.7;25.8)	24.0 (20.5;26.5)	23.3 (21.2;25.4)	24.0 (22.0;26.0)	.389	.966
MDADI-F	19.9 (19.1;20.7)	21.0 (18.0;21.0)	18.5 (16.3;20.8)	20.0 (16.0;21.0)	19.1 (18.1;20.1)	20.0 (18.0;21.0)	.223	.625
MDADI-C	77.8 (72.7;82.9)	80.5 (68.5;87.0)	71.3 (62.8;79.8)	77.0 (61.0;88.0)	72.8 (66.1;79.6)	74.0 (60.0;87.0)	.173	.769
MDADI-P	33.5 (30.3;36.6)	35.0 (28.0;40.0)	29.7 (24.1;35.3)	32.5 (21.0;40.0)	31.2 (26.9;35.4)	32.0 (25.0;40.0)	.217	.668
EAT-10	6.7 (2.7;10.7)	2.5 (0.5;15.0)	6.7 (2.5;10.9)	3.0 (1.0;8.5)	6.3 (2.6;10.0)	3.0 (0.0;13.0)	.594	.149

Abbreviations: MEP, maximum expiratory pressure; PCF, peak cough flow; 9-HPT, 9-Hole Peg Test; PAS, penetration-aspiration scale; TUG, Timed Up and Go test; 25-FW, 25-Foot Walk test; MDADI, The M. D. Anderson Dysphagia Inventory sub scores, emotional (E), functional (F), composite (C), physical (P); EAT-10, The 10-item Eating Assessment Tool.

* $p < .05$.

2.4 | Clinical outcomes

All patients were assessed by board-certified neurologists (R.S., W.S.D., F.E.) who performed neurological evaluations, including manual muscle testing (eye closure, mouth closure, neck flexion/extension, shoulder abduction/external rotation, elbow flexion/extension, wrist flexion/extension, finger extension/abduction, thumb abduction/flexion, deep finger flexion [I-IV], hip flexion/abduction/adduction/extension, knee flexion/extension, ankle dorsiflexion/plantar flexion, toe extension, deep toe flexion) and hand grip strength using a calibrated Jamar Hydraulic Hand Dynamometer. TUG was used to assess each patients mobility, static and dynamic balance, walking ability, and fall risk. 25-FW was administered to assess quantitative mobility and leg function. 9-HPT was used to measure finger dexterity.

A standardized video fluoroscopy swallow study (VFSS) was performed by an American Speech and Hearing Association (ASHA) certified speech language pathologist (SLP) with clinical specialization in swallowing disorders using three food textures of barium contrast (thin, nectar, and pudding), natural sip in the lateral and AP projection. Each patients VFSS was evaluated using the validated Penetration-Aspiration Scale (PAS),⁴⁰ an 8-point ordinal scale of airway safety that describes the degree of airway invasion, the participants response, and whether the invasive material is successfully ejected from the

airway. A PAS score of 1 indicates that no material entered the airway, and a score of 8 indicates that material entered the airway, passed the level of the vocal cords with no effort to eject. MEP and PCF were used to evaluate respiratory function.

2.5 | Statistical analysis

We used SAS Release: 3.8 (Basic Edition) statistics software for statistical analysis and GraphPad Prism 8 for preparing figures. We tabulated summary statistics for the clinical and patient-reported outcomes. Paired T-tests and Wilcoxon signed-rank test were used to compare changes in scores between visits. A *P*-value of less than .05 was considered significant.

3 | RESULTS

We previously published baseline demographics and characteristics of visit 1 of this study.²⁵ In summary, a total of 20 patients, 7 male and 13 female, ages 20–64 y (median 29, interquartile range [IQR], [27:39]) participated in the study. In the initial survey, 12 of 20 (60%) of patients reported some degree of difficulty swallowing and 17 of




FIGURE 1 Distribution of clinical and respiratory outcomes at visits 1, 2, and 3. Box and whisker plots show the median, upper, and lower quartiles, with outlier values shown as black dots. A, distribution of TUG with significant difference between visits 1 and 2. B, Distribution of 25-FW with significant difference between visits 1 and 2. C, Distribution of MEP with significant difference between visits 2 and 3. D, Distribution of peak cough flow with significant difference between visits 2 and 3. * *P*-value < .05 (Wilcoxon signed rank test)

20 (85%) of patients reported some degree of (limb) muscle weakness, primarily in the hands (eg, dropping objects and buttoning). The most severe distal weakness was in the thenar and hypothenar muscles. Neck flexion, shoulder abduction, and hip flexion were weakest among proximal muscles. Additionally, patients had facial and respiratory muscle weakness.

The PAS scores ranged from 1 to 8. Material contacted the vocal cord without clearing the larynx (PAS 5) in one patient, and material entered the trachea without attempt to clear (PAS 8) in two patients.

There were significant differences at visit 1 and 2 between TUG and 25-FW (Table 1, Figure 1). There were no significant changes in EAT-10, MDADI, 9-HPT, grip myometry, or manual muscle strength testing over the course of the observational phase of the study or following the exercise regimen. Two patients had a worsening PAS score from visit 1 to visit 2.

Respiratory outcomes, MEP and PCF, significantly improved following respiratory training program (Table 1, Figure 1). Of seven (7/20) patients who could not generate expiratory pressure greater than 60 cm H₂O at the beginning of the 5-wk trial, five (5/7) patients demonstrated improved ability to expel air through resistance by the end of the study.

Videofluoroscopic evaluation at visit 3 was notable for improvement in the three patients with baseline high PAS scores (visit 2, PAS 8; visit 3, PAS 5) and mild worsening in one patient (visit 2, PAS 1; visit 3, PAS 3). There were no associated changes in patient-reported dysphagia outcomes for these patients. One of three patients with better PAS also had modest improvement in MDADI-e (visit 2, 20; visit 3, 24), MDADI-f (visit 2, 12; visit 3, 17), MDADI-p (visit 2, 18; visit 3, 19), MDADI-c (visit 2, 50; visit 3, 60), and EAT10 (visit 2, 23; visit 3, 20) scores.

4 | DISCUSSION

We previously demonstrated that progressive muscle weakness and dysphagia were common in adult patients with nephropathic cystinosis.^{18,21,22} In the observational phase of this study, we could detect changes in TUG and 25-FW over time. Most of our cohort had distal upper extremity weakness, but the outcome measures used failed to detect a significant change in upper extremity strength. Similarly, clinical and patient-reported dysphagia outcomes failed to capture significant changes over 1 y. Following our respiratory exercise program, patients improved in their respiratory function, which may have reduced aspiration risk in those with more severe dysphagia.

While most participants endorsed a certain degree of difficulty swallowing, the objective swallow testing identified dysphagia only in three patients, raising the possibility that currently used outcome measures lack sensitivity to capture the severity of dysphagia. In this study, we measured severity of dysphagia using PAS, a scale of airway invasion during swallowing only. The most dysphagic patients are those with aspiration/penetration of contrast into the laryngeal vestibule before, during, or after the pharyngeal swallow response. Expansion of our measurements to include ratings of “post swallow residue

in the pharyngeal recesses” and “time of pharyngeal swallow onset and laryngeal closure” may expand the number of patients we classify as having severe dysphagia. Similar to other primarily neuromuscular conditions, the exact pathophysiology and dynamics of dysphagia are not well characterized in nephropathic cystinosis.^{21,22}

Oropharyngeal dysphagia may give rise to aspiration pneumonia and other respiratory complications. In addition, patients living with chronic dysphagia may struggle with the ability to achieve optimal nutrition and hydration, complications that can promote weakness, fatigue, and hospitalization. Patients with cystinosis require an enormous amount of oral medications to manage their disease and post-transplant complications. Depending on the severity of dysphagia, taking these medications several times per day is not only difficult and stressful but can be dangerous.

Extending from more recent studies in patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative processes, we investigated the role of targeted exercise in ameliorating symptoms in the cystinosis population. The impact of EMST in this cohort is similar to that reported in patients with ALS, Parkinsons disease, and multiple sclerosis.^{32,41-44} In the interventional phase of this study, patients with more severe dysphagia showed modest improvements in the PAS score. This may suggest a benefit in more severely affected patients or indicate that the conventional scoring lacks the sensitivity to capture dysphagia in more mildly affected patients.⁴⁰ A multitude of factors may explain the modest decline in PAS of one the patients, including lack of efficacy (only modest improvement in respiratory metrics), overall disease progression, fatigue at the time of testing, or the lack of sensitivity or variability of testing. A more detailed kinematic, temporal, and functional examination of swallowing could help further characterize the underlying pathophysiology and serve as a more sensitive, responsive, and predictive outcome measure.⁴⁵ The exercise was well-tolerated without any major complications. Previous studies in a variety of neurological conditions also showed significant improvement in MEP post-EMST.^{31,32,46,47} Despite improvement in some patients, other studies also found no significant changes in swallowing safety metrics such as PAS, likely pointing to the variable responsiveness and sensitivity of these scoring systems.

Our data must be interpreted in the context of the study design. Although there were statistically significant differences noted between some time points for clinical and respiratory outcomes, there was considerable overlap of the values likely due to the small sample size. Furthermore, both TUG and 25-FW are measures of ambulation, functions that are not typically affected in patients with cystinosis. The lack of association with other measures, such as respiratory and upper extremity outcomes, hampers concept validity of these measures. Additionally, relatively small changes using a measurement with a low signal-to-noise ratio necessitates a larger sample size, a major obstacle in rare diseases.⁴⁸

In nephropathic cystinosis, progressive muscle weakness has emerged as a potential limitation of otherwise effective therapy, such as oral cysteamine treatment. Currently used clinical outcomes and biomarkers lack granularity to capture meaningful changes in disease severity in patients affected by dysphagia and distal myopathy.⁴⁹ A

more extensive longitudinal study would help evaluate the responsiveness of outcome measures used in this study and enable future clinical trial readiness.

ACKNOWLEDGMENTS

This work was supported by a grant from the Cystinosis Research Foundation. We thank the adult cystinosis patients that contributed to the development of the Cystinosis Adult Care Excellence Initiative project, as well as to the patients that participated in this initial study.

ETHICAL PUBLICATION STATEMENT

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

CONFLICTS OF INTEREST

None of the authors have any conflict of interest to disclose.

ORCID

Reza Sadjadi  <https://orcid.org/0000-0003-3829-6030>

REFERENCES

- Ballantyne AO, Trauner DA. Neurobehavioral consequences of a genetic metabolic disorder: visual processing deficits in infantile nephropathic cystinosis. *Neuropsychiatry Neuropsychol Behav Neurol*. 2000;13:254-263.
- Kalatzis V, Cohen-Solal L, Cordier B, et al. Identification of 14 novel CTNS mutations and characterization of seven splice site mutations associated with cystinosis. *Hum Mutat*. 2002;20:439-446.
- Touchman JW, Anikster Y, Dietrich NL, et al. The genomic region encompassing the nephropathic cystinosis gene (CTNS): complete sequencing of a 200-kb segment and discovery of a novel gene within the common cystinosis-causing deletion. *Genome Res*. 2000;10:165-173.
- Gahl WA, Bashan N, Tietze F, Bernardini I, Schulman JD. Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. *Science*. 1982;217:1263-1265.
- Jonas AJ, Smith ML, Schneider JA. ATP-dependent lysosomal cystine efflux is defective in cystinosis. *J Biol Chem*. 1982;257:13185-13188.
- Gahl WA. Cystinosis coming of age. *Adv Pediatr*. 1986;33:95-126.
- Gahl WA, Thoene JG, Schneider JA. Cystinosis. *N Engl J Med*. 2002;347:111-121.
- Dent CE. The amino-aciduria in Fanconi syndrome. A study making extensive use of techniques based on paper partition chromatography. *Biochem J*. 1947;41:240-253.
- Malekzadeh MH, Neustein HB, Schneider JA, et al. Cadaver renal transplantation in children with cystinosis. *Am J Med*. 1977;63:525-533.
- Thoene JG, Oshima RG, Crawhall JC, Olson DL, Schneider JA. Cystinosis. Intracellular cystine depletion by amino thiols in vitro and in vivo. *J Clin Invest*. 1976;58:180-189.
- Gretz N, Manz F, Augustin R, et al. Survival time in cystinosis. A collaborative study. *Proc Eur Dial Transplant Assoc*. 1983;19:582-589.
- Pisoni RL, Thoene JG, Christensen HN. Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts. Role in therapeutic cystine removal? *J Biol Chem*. 1985;260:4791-4798.
- Gahl WA, Reed GF, Thoene JG, et al. Cysteamine therapy for children with nephropathic cystinosis. *N Engl J Med*. 1987;316:971-977.
- Kimonis VE, Troendle J, Rose SR, Yang ML, Markello TC, Gahl WA. Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. *J Clin Endocrinol Metab*. 1995;80:3257-3261.
- Markello TC, Bernardini IM, Gahl WA. Improved renal function in children with cystinosis treated with cysteamine. *N Engl J Med*. 1993;328:1157-1162.
- Gahl WA, Charnas L, Markello TC, Bernardini I, Ishak KG, Dalakas MC. Parenchymal organ cystine depletion with long-term cysteamine therapy. *Biochem Med Metab Biol*. 1992;48:275-285.
- Gahl WA, Balog JZ, Kleta R. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. *Ann Intern Med*. 2007;147:242-250.
- Sonies BC, Almajid P, Kleta R, Bernardini I, Gahl WA. Swallowing dysfunction in 101 patients with nephropathic cystinosis: benefit of long-term cysteamine therapy. *Medicine (Baltimore)*. 2005;84:137-146.
- Charnas LR, Luciano CA, Dalakas M, et al. Distal vacuolar myopathy in nephropathic cystinosis. *Ann Neurol*. 1994;35:181-188.
- Gahl WA, Dalakas MC, Charnas L, et al. Myopathy and cystine storage in muscles in a patient with nephropathic cystinosis. *N Engl J Med*. 1988;319:1461-1464.
- Vester U, Schubert M, Offner G, Brodehl J. Distal myopathy in nephropathic cystinosis. *Pediatr Nephrol*. 2000;14:36-38.
- Sonies BC, Ekman EF, Andersson HC, et al. Swallowing dysfunction in nephropathic cystinosis. *N Engl J Med*. 1990;323:565-570.
- Nesterova G, Gahl W. Nephropathic cystinosis: late complications of a multisystemic disease. *Pediatr Nephrol*. 2008;23:863-878.
- Muller-Felber W, Schroder M, Hirschmann M, Kastrup K, Topfer M, Pongratz D. Neurophysiological testing in long-standing cystinosis. *Electromyogr Clin Neurophysiol*. 1999;39:67-70.
- Sadjadi R, Sullivan S, Grant N, et al. Clinical myopathy in patients with nephropathic cystinosis. *Muscle Nerve*. 2020;61:74-80.
- Trauner DA, Fahmy RF, Mishler DA. Oral motor dysfunction and feeding difficulties in nephropathic cystinosis. *Pediatr Neurol*. 2001;24:365-368.
- Anikster Y, Lacbawan F, Brantly M, et al. Pulmonary dysfunction in adults with nephropathic cystinosis. *Chest*. 2001;119:394-401.
- Connolly MJ. Of proverbs and prevention: aspiration and its consequences in older patients. *Age Ageing*. 2010;39:2-4.
- Pitts T, Bolser D, Rosenbek J, Troche M, Okun MS, Sapienza C. Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson disease. *Chest*. 2009;135:1301-1308.
- Mancopes R, Smaoui S, Steele CM. Effects of expiratory muscle strength training on videofluoroscopic measures of swallowing: a systematic review. *Am J Speech Lang Pathol*. 2020;29:335-356.
- Plowman EK, Tabor-Gray L, Rosado KM, et al. Impact of expiratory strength training in amyotrophic lateral sclerosis: results of a randomized, sham-controlled trial. *Muscle Nerve*. 2019;59:40-46.
- Plowman EK, Watts SA, Tabor L, et al. Impact of expiratory strength training in amyotrophic lateral sclerosis. *Muscle Nerve*. 2016;54:48-53.
- Wang Z, Wang Z, Fang Q, Li H, Zhang L, Liu X. Effect of expiratory muscle strength training on swallowing and cough functions in patients with neurological diseases: a meta-analysis. *Am J Phys Med Rehabil*. 2019;98(12):1060-1066.
- Templeman L, Roberts F. Effectiveness of expiratory muscle strength training on expiratory strength, pulmonary function and cough in the adult population: a systematic review. *Physiotherapy*. 2020;106:43-51.
- Maya Doyle SH, Colleen Hammond, Mack Maxwell, Minnie Sarwal, Serena Scott, Sue Scott, Paula Frye Shal, Susan Thomas. Cystinosis adult care excellence initiative. Executive summary: initial survey results and recommendations. Cystinosis Research Network [serial online] 2016. 2016. Available at: https://www.cystinosis.org/wp-content/uploads/2019/01/Exec_summary.pdf.

36. Doyle M, Werner-Lin A. That eagle covering me: transitioning and connected autonomy for emerging adults with cystinosis. *Pediatr Nephrol*. 2015;30:281-291.
37. Langman CB, Barshop BA, Deschenes G, et al. Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. *Kidney Int*. 2016;89:1192-1203.
38. Werner-Lin MDA. Family strategies for living with rare disease: the experience of cystinosis. *J Soc Soc Work Res*. 2016;7:547-567.
39. Shen SC, Nachalon Y, Randall DR, Nativ-Zeltzer N, Belafsky PC. High elevation training mask as a respiratory muscle strength training tool for dysphagia. *Acta Otolaryngol*. 2019;139:536-540.
40. Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL. A penetration-aspiration scale. *Dysphagia*. 1996;11:93-98.
41. Eom MJ, Chang MY, Oh DH, Kim HD, Han NM, Park JS. Effects of resistance expiratory muscle strength training in elderly patients with dysphagic stroke. *Neurorehabilitation*. 2017;41:747-752.
42. Hegland KW, Davenport PW, Brandimore AE, Singletary FF, Troche MS. Rehabilitation of swallowing and cough functions following stroke: an expiratory muscle strength training trial. *Arch Phys Med Rehabil*. 2016;97:1345-1351.
43. Park JS, Oh DH, Chang MY, Kim KM. Effects of expiratory muscle strength training on oropharyngeal dysphagia in subacute stroke patients: a randomised controlled trial. *J Oral Rehabil*. 2016;43:364-372.
44. Silverman EP, Miller S, Zhang Y, Hoffman-Ruddy B, Yeager J, Daly JJ. Effects of expiratory muscle strength training on maximal respiratory pressure and swallow-related quality of life in individuals with multiple sclerosis. *Mult Scler J Exp Transl Clin*. 2017;3:2055217317710829.
45. Azola ACT, Mulheren R, Mckee G, Christopher-Stine L, Palmer J, Chung TH. Dysphagia in inflammatory myositis: a study of the structural and physiologic changes resulting in disordered swallowing. *American Journal of Physical Medicine & Rehabilitation*. 2020;99(5):404-408.
46. Hutcheson KA, Barrow MP, Plowman EK, et al. Expiratory muscle strength training for radiation-associated aspiration after head and neck cancer: a case series. *Laryngoscope*. 2018;128:1044-1051.
47. Troche MS, Okun MS, Rosenbek JC, et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial. *Neurology*. 2010;75:1912-1919.
48. Froeling M, Nederveen AJ, Nicolay K, Strijkers GJ. DTI of human skeletal muscle: the effects of diffusion encoding parameters, signal-to-noise ratio and T2 on tensor indices and fiber tracts. *NMR Biomed*. 2013;26:1339-1352.
49. Lunn MP, Van den Bergh PY. Outcome measures in neuromuscular disease: is the world still flat? *J Peripher Nerv Syst*. 2015;20:255-259.

How to cite this article: Sadjadi R, Sullivan S, Grant N, et al. Clinical trial readiness study of distal myopathy and dysphagia in nephropathic cystinosis. *Muscle & Nerve*. 2020;1-7. <https://doi.org/10.1002/mus.27039>